Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Bioeq IP AG.

    Client Virtual Booth

    BIOEQ IP AG

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Bioeq IP AG
    Switzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Waldmannstrasse 8 8001 Zurich
    Telephone
    Telephone
    +41 44 533 41 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://bioeq.ch/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/bioeq-ip-ag
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    European Commission Approves FYB201/Ranivisio®1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis®2

    Details:

    Ranivisio (ranibizumab) is indicated for the treatment of neovascular (wet) age-related macular degeneration, treatment of visual impairment due to diabetic macular oedema or choroidal neovascularization, proliferative diabetic retinopathy, as well as visual impairment.


    Lead Product(s): Ranibizumab

    Therapeutic Area: Ophthalmology Product Name: Ranivisio

    Highest Development Status: ApprovedProduct Type: Large molecule

    Recipient: Teva Pharmaceutical Industries

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 29, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    United Kingdom First to Grant Licence for Teva’s Ophthalmology Biosimilar Ongavia (ranibizumab)

    Details:

    MHRA granted a licence for Ongavia® (ranibizumab), a biosimilar to Lucentis®*, for the treatment of (wet) age-related macular degeneration (AMD) and several other eye diseases, such as diabetic macular oedema and proliferative diabetic retinopathy.


    Lead Product(s): Ranibizumab

    Therapeutic Area: Ophthalmology Product Name: Ongavia

    Highest Development Status: ApprovedProduct Type: Large molecule

    Recipient: Teva Pharmaceutical Industries

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 17, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Polpharma Biologics Group Announces That Its Joint Venture Company Bioeq Has Submitted A Biologics License Application (BLA) to the FDA For The Ranibizu...

    Details:

    FYB201 (Ranibizumab) is used in treatment of various eye diseases in adults which cause damage to retina, thereby impairing vision. In these diseases, protein called VEGF causes excessive blood vessels to form within retina, resulting in a progressive loss of central vision.


    Lead Product(s): Ranibizumab

    Therapeutic Area: Ophthalmology Product Name: FYB201

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Formycon

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 06, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Formycon and Bioeq Announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara (Ustekinumab)

    Details:

    The aim of the randomized, double-blind, multi-center Phase III study is to demonstrate the comparability of FYB202 and the reference product Stelara(R) in terms of efficacy, safety and immunogenicity in patients with moderate to severe psoriasis vulgaris.


    Lead Product(s): Ustekinumab

    Therapeutic Area: Dermatology Product Name: FYB202

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Recipient: Formycon

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 09, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search